259 related articles for article (PubMed ID: 33028115)
21. Early response to erythropoiesis-stimulating agents in non-dialysis chronic kidney disease patients.
Kuwahara M; Arai Y; Takehara E; Sasaki Y; Yoshimine T; Kusaka K; Shikuma S; Akita W; Uchida S
Clin Exp Nephrol; 2016 Aug; 20(4):585-594. PubMed ID: 26511877
[TBL] [Abstract][Full Text] [Related]
22. Canadian Society of Nephrology commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD.
Moist LM; Troyanov S; White CT; Wazny LD; Wilson JA; McFarlane P; Harwood L; Sood MM; Soroka SD; Bass A; Manns BJ
Am J Kidney Dis; 2013 Nov; 62(5):860-73. PubMed ID: 24054466
[TBL] [Abstract][Full Text] [Related]
23. New Treatment Approaches for the Anemia of CKD.
Bonomini M; Del Vecchio L; Sirolli V; Locatelli F
Am J Kidney Dis; 2016 Jan; 67(1):133-42. PubMed ID: 26372086
[TBL] [Abstract][Full Text] [Related]
24. Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients.
Piotr B; Mariusz S; Jacek R
Curr Pharm Biotechnol; 2017; 18(4):303-308. PubMed ID: 28137221
[TBL] [Abstract][Full Text] [Related]
25. Treatment and costs associated with anemic chronic kidney disease patients.
Rasu RS; Crawford T; Manley H; Balkrishnan R
Curr Med Res Opin; 2008 Jan; 24(1):129-37. PubMed ID: 18034919
[TBL] [Abstract][Full Text] [Related]
26. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.
Bennett CL; Silver SM; Djulbegovic B; Samaras AT; Blau CA; Gleason KJ; Barnato SE; Elverman KM; Courtney DM; McKoy JM; Edwards BJ; Tigue CC; Raisch DW; Yarnold PR; Dorr DA; Kuzel TM; Tallman MS; Trifilio SM; West DP; Lai SY; Henke M
JAMA; 2008 Feb; 299(8):914-24. PubMed ID: 18314434
[TBL] [Abstract][Full Text] [Related]
27. Impact of a clinical pharmacy anemia management service on adherence to monitoring guidelines, clinical outcomes, and medication utilization.
Debenito JM; Billups SJ; Tran TS; Price LC
J Manag Care Spec Pharm; 2014 Jul; 20(7):715-20. PubMed ID: 24967524
[TBL] [Abstract][Full Text] [Related]
28. Variation in health plan coverage of ESAs for anemia due to chronic kidney disease.
Margaretos NM; Panzer AD; Lai RC; Sanon M; Michalopoulos E; Redmond AM; Moghadam R; Chambers JD
J Manag Care Spec Pharm; 2021 Sep; 27(9):1221-1229. PubMed ID: 34464213
[No Abstract] [Full Text] [Related]
29. Cardiovascular safety of current and emerging drugs to treat anaemia in chronic kidney disease: a safety review.
Locatelli F; Paoletti E; Del Vecchio L
Expert Opin Drug Saf; 2023; 22(12):1179-1191. PubMed ID: 38111209
[TBL] [Abstract][Full Text] [Related]
30. Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy.
Trotta F; Belleudi V; Fusco D; Amato L; Mecozzi A; Mayer F; Sansone M; Davoli M; Addis A
BMJ Open; 2017 Mar; 7(3):e011637. PubMed ID: 28283484
[TBL] [Abstract][Full Text] [Related]
31. Latest strategy in renal anemia management in peritoneal dialysis patients.
Lo WK
Perit Dial Int; 2008 Jun; 28 Suppl 3():S76-80. PubMed ID: 18552270
[TBL] [Abstract][Full Text] [Related]
32. Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study.
Martínez-Castelao A; Cases A; Carballada AT; Iranzo JT; Bronsoms J; Vallès-Prats M; Monserrat DT; Jimenez EM;
Nefrologia; 2015; 35(2):179-88. PubMed ID: 26300512
[TBL] [Abstract][Full Text] [Related]
33. Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients.
Wang B; Yin Q; Han YC; Wu M; Li ZL; Tu Y; Zhou LT; Wei Q; Liu H; Tang RN; Cao JY; Lv LL; Liu BC
Ren Fail; 2020 Nov; 42(1):912-925. PubMed ID: 32869703
[TBL] [Abstract][Full Text] [Related]
34. Biosimilar Erythropoiesis-Stimulating Agents in Chronic Kidney Disease.
Shah HH; Fishbane S
Adv Chronic Kidney Dis; 2019 Jul; 26(4):267-271. PubMed ID: 31477257
[TBL] [Abstract][Full Text] [Related]
35. Protocol of a randomized controlled trial of an erythropoietin stimulating agent decision aid for anemia treatment in kidney disease.
Beach LB; Wild M; Ramachandran G; Ikizler HO; Cavanaugh KL
BMC Nephrol; 2016 Jul; 17(1):86. PubMed ID: 27430294
[TBL] [Abstract][Full Text] [Related]
36. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update.
Rizzo JD; Somerfield MR; Hagerty KL; Seidenfeld J; Bohlius J; Bennett CL; Cella DF; Djulbegovic B; Goode MJ; Jakubowski AA; Rarick MU; Regan DH; Lichtin AE
Blood; 2008 Jan; 111(1):25-41. PubMed ID: 17954703
[TBL] [Abstract][Full Text] [Related]
37. The Effect of Erythropoietin-Stimulating Agents on Health-Related Quality of Life in Anemia of Chronic Kidney Disease: A Systematic Review and Meta-analysis.
Collister D; Komenda P; Hiebert B; Gunasekara R; Xu Y; Eng F; Lerner B; Macdonald K; Rigatto C; Tangri N
Ann Intern Med; 2016 Apr; 164(7):472-8. PubMed ID: 26881842
[TBL] [Abstract][Full Text] [Related]
38. New expectations in the treatment of anemia in chronic kidney disease.
López-Gómez JM; Abad S; Vega A
Nefrologia; 2016; 36(3):232-6. PubMed ID: 27137103
[TBL] [Abstract][Full Text] [Related]
39. Anemia management in cancer patients with chronic kidney disease.
Deak AT; Troppan K; Rosenkranz AR
Eur J Intern Med; 2016 Dec; 36():13-19. PubMed ID: 27640913
[TBL] [Abstract][Full Text] [Related]
40. Anemia Management in the Cancer Patient With CKD and End-Stage Kidney Disease.
Rashidi A; Garimella PS; Al-Asaad A; Kharadjian T; Torres MN; Thakkar J
Adv Chronic Kidney Dis; 2022 Mar; 29(2):180-187.e1. PubMed ID: 35817525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
